Nuformix PLC · LSE:NFX
Nuformix — Investor Presentation (April 2021)
23 slides from Nuformix's investor presentation, April 2021
Slide 1: Unlocking the Potential of Therapeutics for Fibrosis & Oncology
Unlocking the Potential of Therapeutics for Fibrosis & Oncology Corporate Presentation – April 2021
Slide 2: Disclaimer
Disclaimer This document has been prepared by Nuformix plc (the "Company") and is being made available for the sole purpose of providing the recipients with background information about the Company. It does not constitute or form part of any offer or invitation to sell or issue or any solicitation o
Slide 3: Expertise in Repurposing Allows Nuformix to Maximise Commercial Opportunities
Expertise in Repurposing Allows Nuformix to Maximise Commercial Opportunities Discovery, development and IP protection of new, differentiated uses of existing drugs Enhancing the Potential advantages Making a difference to therapeutic potential and due to existing data, patients commercial value of
Slide 4: Business highlights
Business highlights Targeting fibrosis and Pipeline of Preclinical / Phase 1 oncology ready assets with significant value potential and potential for early licensing opportunities Innovative product Lead asset NXP002 (inhaled concepts with commercial tranilast) – novel inhaled potential, addressing
Slide 5: Highly Experienced Executive Leadership and Board (as at April 2021)
Highly Experienced Executive Leadership and Board (as at April 2021) EXECUTIVE LEADERSHIP Dr Anne Brindley Dr Joanne Holland Chief Executive Officer Chief Scientific Officer & a Co-Founder • Over 30 years in Big Pharma and Biotech with • Over 18 years experience in R&D, IP & commercial extensive exp
Slide 6: Nuformix Strategy
Nuformix Strategy Unlocking the potential of therapeutics for fibrosis & oncology Accelerate value creation through Business Development & Licensing Optimise value from existing assets, with prioritised use of cash & tight financial control* Progress further activities on Further research on NXP002
Slide 7: Business Model
Business Model Extensive drug Virtual development Rigorous business development and via strong network development repurposing expertise of contractors Identify / IP generation Value Value create new / Preclinical / inflexion added point – product early clinical licensing / to concepts development p
Slide 8: Nuformix Pipeline
Nuformix Pipeline Project / indication / IP generation Preclinical Phase 1 route of administration NXP002 IPF Inhaled tranilast NXP001 Oncology Oral aprepitant BD activity (license option to Oxilio) NXP004 Oncology BD activity Oral (undisclosed drug) 8
Slide 9: NXP002 (Inhaled Tranilast) in Idiopathic Pulmonary Fibrosis
NXP002 (Inhaled Tranilast) in Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis NXP002 (Inhaled Tranilast) (IPF) • Devastating, progressive disease caused • Potential novel inhaled treatment for by scarring (fibrosis) in the lung IPF • Affects 3 million people worldwide, • Potential for Or
Slide 10: IPF Disease Process and Physiology
IPF Disease Process and Physiology Smoke, pollution, acid Death from respiratory failure Lung tissue injury (suffocation) Inflammation, excessive wound healing Patients become breathless, Fibrosis, scarring wheelchair bound and require oxygen Reduced gas exchange 10
Slide 11: Significant Commercial Opportunity in IPF
Significant Commercial Opportunity in IPF Fast-growing market driven by orally IPF market in 7 major markets1: Largest delivered Ofev® (nintedanib) & Esbriet® market is US, followed by UK, Italy, Japan, (pirfenidone) Germany, France, Spain US launches 2014 Global Sales 8.4% CAGR • Esbriet: 2020 CHF
Slide 12: IPF attracts many deals in early clinical stage and more recently in preclinical stage (1)
IPF attracts many deals in early clinical stage and more recently in preclinical stage (1) Licensee / deal type / asset Acquirer / Stage at time of Data at time Value USD Upfront USD partner deal of deal m incl m upfronts Morphic Therapeutics Abbvie 2018 – Preclinical Preclinical undisclosed 100 (li
Slide 13: IPF attracts many deals in early clinical stage and more recently in preclinical stage (2)
IPF attracts many deals in early clinical stage and more recently in preclinical stage (2) Licensee / deal type / asset Acquirer / Stage at Data at time Value USD m incl Upfront partner time of deal of deal upfronts USD m Arresto (company acquired) Gilead 2011 In Phase 1 Safety/PK in 225 (Simtuzumab
Slide 14: Preclinical Data Supports Potential of Tranilast in IPF
Preclinical Data Supports Potential of Tranilast in IPF Literature data in numerous models supports use of tranilast in fibrosis Oral tranilast bleomycin (BLM) study (mouse) - Tranilast in NASH model of liver fibrosis2 model for IPF1 NFX data on NXP002 also supports its use in IPF - demonstrated tha
Slide 15: NXP002 (Inhaled Tranilast) – Development Plan
NXP002 (Inhaled Tranilast) – Development Plan Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2021 2022 2023 PRECLINICAL PHASE 1 PHASE 2 Inhalati No on n- Feasibil GL GLP Phase 1 ity P Today Feasibility Non-GLP Phase 1 Phase 1 package package ready package package Development related inflexion points offer mult
Slide 16: NXP001 (aprepitant)
NXP001 (aprepitant) Marketed drug NXP001 • Oral drug for Oncology • Novel form with improved Supportive Care properties • Poor physical properties, • Granted patent attained needs complex formulation • NFX data from Phase 1 study • Literature data on potential demonstrates bioavailability in other i
Slide 17: NXP004
NXP004 Marketed drug NXP004 • Oral drug with blockbuster • Novel form with improved sales and growth for properties Oncology • Further research ongoing to • Poor physical properties, characterise and elucidate needs complex formulation advantages • Patent protected • One patent application filed – f
Slide 18: Recent Successful Placing and Use of Funds
Recent Successful Placing and Use of Funds Placing • Equity placing raised c.£1.5m gross (March 2021) Use of funds • Develop preclinical data package for lead asset NXP002 • Staged investment approach with several options to license • NXP004 – further research followed by business development • Addi
Slide 19: Summary
Summary Focus New therapies with attractive commercial potential in fibrosis and oncology Potential to derive value in the short- Assets term through further development and /or BD and licensing Strengthened leadership with extensive Management and relevant experience Low cost base Fully virtual ope
Slide 20: Appendices
Appendices
Slide 21: Company Summary
Company Summary • Founded in 2008 and listed on London Stock Exchange (LSE: NFX) in 2017 • Fully virtual operating model with low operating costs Market Cap (April Substantial 2021) shareholders (April c.£14m 2021 figures): CPI Enterprises1 Brief financials (H1 2020) 6.7% • Total revenue £195,550 (H
Slide 22: Repurposing examples – deals
Repurposing examples – deals Repurposed Product change Acquirer/ Stage at time Deal Value Company Drug Original indication Upfront (USD) indication from original Licensor (Year) of deal (USD) Vicept Rhofade Rosacea Decongestant New indication + Allergan Phase II 200 million 75 million Therapeutics (
Slide 23: Repurposing examples – products
Repurposing examples – products Annual revenues Company Drug Repurposed indication Original indication Product differentiation Notes (USD) Tecfidera Biogen Multiple Sclerosis Psoriasis (topical) New route (oral) 4.43 billion (2019) (dimethylfumarate) Barhemsys Post operative nausea 400 million Acaci